GlassScriptPhysician profile
Carla Ellen Holmes
NPI 1356850887
$7,018.52
in general payments reported to CMS, 2019-2025
55 companies · $3,237 in 2025
The $3,237 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $775 · 2023: $958 · 2024: $1,520 · 2025: $3,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,336 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,336.09 |
| Education | $377.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $721.42 | 2021-2024 | Linq II, Pulseselect |
| Novartis Pharmaceuticals Corporation | $490.04 | 2021-2025 | |
| Boston Scientific Corporation | $484.64 | 2022-2023 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $469.09 | 2021-2025 | Calquence, Tagrisso |
| Janssen Pharmaceuticals, INC | $455.71 | 2021-2024 | Xarelto |
| Daiichi Sankyo INC. | $370.24 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $260.18 | 2024-2025 | Darzalex, Tecvayli, Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $244.46 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $240.32 | 2021-2025 | Breyanzi, Opdualag, Opdivo |
| Abbott Laboratories | $240.02 | 2022-2024 | Aveir |
| Incyte Corporation | $193.22 | 2024-2025 | Monjuvi, Pemazyre, Zynyz |
| Eisai INC. | $185.70 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $170.90 | 2021-2025 | Keytruda, Welireg |
| Astellas Pharma US INC | $162.95 | 2024-2025 | Padcev, Xtandi |
| Amgen INC. | $162.81 | 2023-2024 | Repatha |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $135.37 | 2021-2025 | |
| Lilly USA, LLC | $131.64 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Cvrx, INC. | $130.78 | 2023 | Barostim Neo System |
| Celgene Corporation | $119.82 | 2025 | Reblozyl, Opdualag, Opdivo |
| Pfizer INC. | $110.27 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.27 | 2022-2024 | Lifevest |
| Seagen INC. | $99.99 | 2025 | |
| Acrotech Biopharma INC. | $82.19 | 2025 | Beleodaq |
| Glaxosmithkline, LLC. | $78.99 | 2024-2025 | Ojjaara, Blenrep, Zejula |
| Philips North America LLC | $73.92 | 2024 | (5091) Amb Mon & Diag Und |
| Beigene USA, INC. | $70.15 | 2024-2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.71 | 2021-2024 | Gilotrif |
| Genentech USA, INC. | $65.48 | 2021-2025 | Venclexta, Phesgo |
| Exelixis INC. | $61.14 | 2024-2025 | Cabometyx |
| Alnylam Pharmaceuticals INC. | $59.79 | 2024-2025 | Givlaari |
| Jazz Pharmaceuticals INC. | $58.46 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.50 | 2024-2025 | Fruzaqla, Ninlaro |
| Pharmacosmos Therapeutics INC. | $56.66 | 2024-2025 | Monoferric, Cosela |
| Abbvie INC. | $49.79 | 2025 | |
| Emd Serono, INC. | $48.42 | 2024-2025 | |
| Sobi, INC | $46.12 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $40.65 | 2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $39.79 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Adc Therapeutics America, INC. | $38.07 | 2025 | |
| Tersera Therapeutics LLC | $36.68 | 2025 | Xermelo |
| Array Biopharma INC | $34.44 | 2025 | Mektovi, Braftovi, Lorbrena |
| Kyowa Kirin, INC. | $34.15 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.00 | 2024 | Relistor |
| Azurity Pharmaceuticals, INC. | $22.87 | 2025 | Danziten |
| Accord Healthcare, INC. | $21.68 | 2025 | |
| Aveo Pharmaceuticals, INC. | $21.65 | 2025 | |
| Geron Corporation | $19.58 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $18.27 | 2025 | |
| Tactile Systems Technology INC | $17.36 | 2025 | Flexitouch Plus, Nimbl |
| Springworks Therapeutics, INC. | $17.15 | 2025 | Ogsiveo |
| Coherus Oncology, INC. | $16.46 | 2021 | |
| Beone Medicines USA, INC. | $15.56 | 2025 | Brukinsa |
| Biotronik INC. | $15.12 | 2021 | |
| Genzyme Corporation | $14.30 | 2024 | |
| Pharmaessentia USA Corporation | $13.58 | 2024 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.